Receptor Targets in Modern Pharmacotherapy: Mechanisms, Modulators, And Therapeutic Potential

Abstract

The evolution of pharmacotherapy is intricately linked to advancements in our understanding of receptor biology. Receptors, as molecular sensors embedded within or on the surface of cells, serve as critical mediators through which endogenous ligands (such as hormones and neurotransmitters) and exogenous agents (including drugs and toxins) influence and regulate diverse physiological processes. Modern therapeutics has increasingly focused on targeting these receptors to modulate specific signaling pathways with precision. This review provides a comprehensive overview of the major classes of receptors—such as G protein-coupled receptors (GPCRs), ion channels, nuclear receptors, enzyme-linked receptors, and cytokine receptors—and explores their pharmacological significance in the treatment of various diseases. The mechanisms by which these receptors transmit signals, including ligand binding, conformational changes, and downstream signaling cascades, are discussed in detail. We further highlight the role of key receptor modulators, such as agonists, antagonists, partial agonists, and inverse agonists, in advancing clinical outcomes across therapeutic areas like oncology, neurology, cardiology, and immunology. Emerging concepts like biased agonism, which allows selective pathway activation, and allosteric modulation, which provides receptor specificity and enhanced safety profiles, are also examined. Additionally, the phenomenon of receptor desensitization and its impact on drug efficacy and tolerance is addressed. Recent innovations in receptor-targeted drug discovery have been propelled by the integration of advanced technologies, including cryo-electron microscopy (Cryo-EM), molecular docking, artificial intelligence-driven drug design, and systems pharmacology. These tools have significantly improved our ability to model receptor structures, predict ligand-receptor interactions, and identify novel therapeutic candidates. Ultimately, a deep understanding of receptor pharmacodynamics, combined with the application of cutting-edge technologies, holds the promise of ushering in a new era of precision and personalized medicine. By tailoring receptor-targeted therapies to individual patient profiles, the next generation of pharmacological interventions aims to achieve greater efficacy, minimized side effects, and improve overall patient outcomes.

Keywords

Introduction

Receptors are specialized macromolecular structures, predominantly proteins, that serve as key mediators in the communication between cells and their external environment. These molecular entities detect and respond to a wide range of endogenous chemical signals—such as hormones, neurotransmitters, and growth factors—as well as exogenous substances, including drugs and toxins. Upon activation by a specific ligand, receptors undergo conformational changes that trigger intracellular signaling cascades, ultimately leading to physiological or pathological outcomes. The foundational concept of receptors has revolutionized the field of pharmacology. Historically, drug discovery was largely empirical, relying on serendipity and broad-spectrum activity without a clear understanding of the underlying mechanisms. The recognition of receptors as discrete and selective drug targets has shifted pharmacotherapy toward a more rational, mechanism-based approach. This paradigm shift has enabled the design of drugs with greater specificity, efficacy, and safety by selectively modulating receptor function. Receptors are now considered central to the pharmacodynamics of most therapeutic agents. More than 40% of all marketed drugs act through receptor targets, underscoring their critical role in clinical medicine. These include a diverse array of receptor families such as G protein-coupled receptors (GPCRs), ionotropic and metabotropic receptors, nuclear hormone receptors, receptor tyrosine kinases, and cytokine receptors, each with distinct structural and functional attributes. This review aims to explore the strategies employed in modern drug development to harness receptor biology. We will examine the various classes of receptors, the nature of drug-receptor interactions, and how these interactions translate into therapeutic effects. Additionally, we will explore the concepts of receptor modulation, including agonism, antagonism, allosteric regulation, and receptor desensitization. Finally, we highlight recent advances in receptor-targeted therapy, driven by innovations in structural biology, computational pharmacology, and systems-level modelling. Understanding receptor pharmacology not only facilitates the development of novel therapeutics but also paves the way for precision medicine, wherein treatments can be tailored to individual receptor profiles and genetic backgrounds. As such, receptors remain at the forefront of pharmaceutical research and clinical intervention.

2. Classification of Receptors

Receptors are molecular gatekeepers that mediate signal transduction between extracellular stimuli and intracellular responses. Based on their structure, location, mechanism of action, and the nature of their ligands, receptors are broadly classified into the following major categories:

2.1 G-Protein Coupled Receptors (GPCRs)

G-Protein Coupled Receptors (GPCRs) constitute the largest and most versatile family of membrane-bound receptors, representing approximately 40% of all known drug targets. These seven-transmembrane domain receptors interact with heterotrimeric G-proteins upon ligand binding, leading to the activation or inhibition of downstream signaling pathways such as adenylyl cyclase, phospholipase C, and various ion channels. GPCRs are involved in a wide range of physiological processes including cardiovascular regulation, neurotransmission, and sensory perception. Clinically relevant examples include:

• β-adrenergic receptors (targeted in hypertension and asthma),
• Dopamine receptors (targeted in Parkinson's disease and schizophrenia),
• Opioid receptors (targeted in pain management).

2.2 Ion Channel Receptors

Also known as ligand-gated ion channels, these receptors regulate the flow of ions such as Na?, K?, Ca²?, and Cl? across the plasma membrane in response to ligand binding. Ion channel receptors are essential for rapid synaptic transmission, muscle contraction, and excitability in neurons and myocytes. Examples include:

• Nicotinic acetylcholine receptors (nAChRs), which mediate neuromuscular transmission,
• γ-Aminobutyric acid type A (GABA_A) receptors, which are critical for inhibitory neurotransmission in the central nervous system.

2.3 Enzyme-Linked Receptors

These receptors possess intrinsic enzymatic activity or are closely associated with intracellular enzymes. The most prominent subcategory is Receptor Tyrosine Kinases (RTKs), which undergo autophosphorylation upon ligand binding and activate signaling cascades such as the MAPK and PI3K-Akt pathways. These receptors play pivotal roles in cell proliferation, survival, and differentiation. Therapeutic examples include:

• Epidermal Growth Factor Receptor (EGFR), targeted in non-small cell lung cancer,
• Vascular Endothelial Growth Factor Receptor (VEGFR), targeted in anti-angiogenic cancer therapy.

2.4 Nuclear Receptors

Unlike membrane-bound receptors, nuclear receptors are intracellular proteins that directly modulate gene transcription upon ligand binding. These receptors typically respond to lipophilic hormones and vitamins, translocate to the nucleus, and bind to specific DNA sequences called hormone response elements (HREs). Their actions are slower but long-lasting. Key examples include:

• Glucocorticoid receptors, targeted in inflammation and autoimmune diseases,
• Estrogen receptors, targeted in hormone-dependent cancers like breast cancer.

2.5 Toll-like Receptors and Pattern Recognition Receptors (PRRs)

These receptors are integral components of the innate immune system. They recognize pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), initiating inflammatory responses. Toll-like receptors (TLRs), in particular, are expressed on immune and non-immune cells and play crucial roles in host defense and immune surveillance. Examples include:

• TLR4, which detects bacterial lipopolysaccharide (LPS),
• TLR9, which senses unmethylated CpG DNA.

3. Mechanisms of Receptor Activation and Modulation

Receptors are dynamic molecular structures capable of adopting multiple conformational states in response to ligand binding. The interaction between a ligand and its receptor can result in a variety of functional outcomes depending on the ligand's efficacy and the receptor's conformational flexibility. Understanding these mechanisms is central to rational drug design, allowing for the development of compounds with desired therapeutic profiles and minimal side effects. The principal mechanisms of receptor modulation include:

3.1 Agonism

Agonists are ligands that bind to the active (orthosteric) site of a receptor and stabilize its active conformation, thereby triggering a biological response. Agonists may mimic the action of endogenous ligands or be synthetic compounds designed to enhance physiological processes.
Example: Salbutamol, a β2-adrenergic receptor agonist, stimulates bronchodilation in asthma by activating cyclic AMP (cAMP) pathways in bronchial smooth muscle cells.

3.2 Antagonism

Antagonists bind to receptors without eliciting a cellular response. Instead, they competitively or non-competitively inhibit the action of endogenous agonists by occupying the binding site or altering receptor conformation.
Example: Atenolol, a selective β1-adrenergic receptor antagonist, prevents sympathetic stimulation of the heart, thus reducing heart rate and blood pressure in hypertensive patients.

3.3 Partial Agonism

Partial agonists bind and activate receptors but produce a submaximal response even at full receptor occupancy. These agents can act as agonists in the absence of full agonists or as functional antagonists in their presence by competing for receptor binding.
Example: Buprenorphine, a partial agonist at μ-opioid receptors, provides analgesia with a lower risk of respiratory depression compared to full agonists like morphine.

3.4 Inverse Agonism

Inverse agonists bind to receptors that exhibit constitutive (basal) activity in the absence of a ligand and stabilize their inactive conformation, thereby suppressing this baseline activity. This mechanism is distinct from antagonism as it actively reduces receptor signaling below the basal level.
Example: Cetirizine, a second-generation antihistamine, acts as an inverse agonist at H1 receptors, reducing allergic responses more effectively than simple antagonists.

3.5 Allosteric Modulation

Allosteric modulators bind to sites on the receptor that are topographically distinct from the orthosteric (active) binding site. These agents do not directly activate the receptor but modulate the receptor's response to the endogenous ligand. Positive allosteric modulators (PAMs) enhance receptor activation, while negative allosteric modulators (NAMs) inhibit it.
Example: Benzodiazepines, such as diazepam, act as PAMs at GABA_A receptors, increasing the receptor's affinity for GABA and enhancing inhibitory neurotransmission in the CNS.

These mechanisms illustrate the versatility of receptor pharmacology and highlight the importance of ligand-receptor interactions in designing targeted therapeutics. Understanding such nuances not only aids in predicting clinical outcomes but also allows for the refinement of drug properties to achieve selective and tailored pharmacological effects.

4. Modern Approaches to Receptor Targeting

The evolution of receptor pharmacology has moved beyond traditional ligand-receptor models to incorporate more nuanced and sophisticated strategies. These modern approaches aim to enhance therapeutic efficacy, minimize adverse effects, and achieve greater specificity in modulating receptor activity. The following mechanisms represent some of the most promising innovations in the field:

4.1 Biased Agonism (Functional Selectivity)

Biased agonism, also referred to as functional selectivity or ligand-directed signaling, describes the ability of a ligand to selectively activate certain signaling pathways over others through the same receptor. This occurs due to conformational diversity in receptor states induced by different ligands. By favoring beneficial pathways while avoiding those associated with side effects, biased agonists offer a significant therapeutic advantage.
Example: TRV130 (oliceridine) is a biased ligand at the μ-opioid receptor that preferentially activates G protein signaling while minimizing β-arrestin recruitment. This selective signaling reduces the risk of opioid-induced respiratory depression and constipation—common side effects associated with traditional opioids.

4.2 Allosteric Modulators

Allosteric modulation involves ligands that bind to sites distinct from the orthosteric (primary) binding site on the receptor. These modulators influence receptor conformation and function indirectly, thereby offering unique advantages such as improved subtype selectivity, saturation of effect (ceiling effect), and preservation of physiological regulation by the endogenous ligand. Allosteric modulators can be:

• Positive Allosteric Modulators (PAMs) – Enhance the effect of the endogenous ligand.
• Negative Allosteric Modulators (NAMs) – Dampen receptor activity.
• Silent Allosteric Modulators (SAMs) – Occupy allosteric sites without functional consequence but may block other allosteric modulators.

Example: Cinacalcet is a PAM of the calcium-sensing receptor (CaSR), used in treating secondary hyperparathyroidism. It increases the receptor's sensitivity to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion without mimicking calcium itself.

4.3 Receptor Desensitization and Downregulation

Prolonged or repeated exposure to agonists can lead to receptor desensitization—a state where the receptor becomes less responsive to stimulation. This is often followed by receptor internalization (endocytosis) and downregulation (degradation or decreased synthesis), resulting in diminished pharmacological response over time. These adaptive processes are critical considerations in the chronic use of certain drugs, especially when therapeutic tolerance is a concern.
Example: Chronic use of β2-adrenergic agonists, such as salbutamol in asthma therapy, can lead to desensitization of β2-receptors, reducing bronchodilatory efficacy and potentially necessitating dose escalation or combination therapy.

5. Therapeutic Areas with Receptor-Based Interventions

Receptor-targeted therapies form the cornerstone of modern pharmacotherapy across diverse clinical domains. By modulating specific receptors involved in disease pathogenesis, these agents offer targeted, mechanism-based interventions that improve efficacy and reduce systemic toxicity. Below is an overview of key therapeutic areas where receptor modulation has had a transformative impact:

5.1 Cardiovascular Disorders

Cardiovascular diseases often involve dysregulation of autonomic signaling and hormonal pathways, making receptor targeting a critical strategy.

• β-Adrenergic Receptor Antagonists (β-Blockers):
  Drugs like metoprolol and atenolol selectively block β1-adrenergic receptors, reducing heart rate, myocardial oxygen demand, and blood pressure. They are widely used in the treatment of hypertension, angina, and heart failure.
• Angiotensin II Receptor Blockers (ARBs):
  Agents such as losartan and valsartan antagonize the AT1 subtype of angiotensin II receptors, thereby promoting vasodilation and reducing aldosterone-mediated sodium retention. ARBs are central to managing hypertension and chronic heart failure.

5.2 Neurological and Psychiatric Disorders

Central nervous system disorders often result from imbalances in neurotransmitter-receptor interactions, making receptor modulation vital in their management.

• Dopamine D2 Receptor Antagonists:
  Haloperidol and other typical antipsychotics block D2 receptors in the mesolimbic pathway, alleviating positive symptoms of schizophrenia.
• Selective Serotonin Reuptake Inhibitors (SSRIs):
  Though not direct receptor agonists, SSRIs like fluoxetine increase serotonin availability in the synaptic cleft, indirectly enhancing 5-HT receptor activity, particularly 5-HT1A, which contributes to antidepressant effects.

5.3 Oncology

Cancer therapy has increasingly focused on receptors involved in cell proliferation, survival, and metastasis.

• Epidermal Growth Factor Receptor (EGFR) Inhibitors:
  Erlotinib is a tyrosine kinase inhibitor (TKI) targeting EGFR, used in non-small cell lung cancer (NSCLC).
• HER2/neu Receptor Antagonists:
  Trastuzumab, a monoclonal antibody against HER2, is effective in HER2-positive breast cancers by blocking receptor-mediated mitogenic signaling.

5.4 Endocrine and Metabolic Disorders

Receptors that regulate metabolism, insulin sensitivity, and hormone secretion are critical therapeutic targets in endocrine diseases.

• GLP-1 Receptor Agonists:
  Liraglutide mimics the incretin hormone GLP-1, enhancing insulin secretion, suppressing glucagon, and reducing appetite. It is used in type 2 diabetes and obesity management.
• Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Agonists:
  Pioglitazone activates PPARγ nuclear receptors, improving insulin sensitivity in adipose tissue and muscles, and is used in type 2 diabetes and metabolic syndrome.

5.5 Immunotherapy

In recent years, receptor-targeted immunotherapies have revolutionized oncology and autoimmune disease treatment by modulating immune checkpoints.

• Immune Checkpoint Inhibitors (ICIs):
  Drugs like pembrolizumab target the programmed death-1 (PD-1) receptor or its ligand PD-L1, preventing inhibitory signaling in T-cells. This restores anti-tumor immunity in cancers such as melanoma, NSCLC, and renal cell carcinoma.

6. Drug Discovery Strategies for Receptor Targets

The process of identifying and optimizing therapeutics that modulate receptor function has evolved significantly with advances in molecular biology, structural pharmacology, and computational sciences. Modern drug discovery integrates a range of strategies to enhance efficiency, specificity, and success rates in developing receptor-targeted agents. Key strategies include:

6.1 High-Throughput Screening (HTS)

High-throughput screening is a powerful technique that enables the rapid evaluation of thousands to millions of compounds for their activity against specific receptor targets. HTS assays can be biochemical or cell-based and are often automated, allowing for efficient identification of potential lead compounds.
This method is particularly useful in the early stages of drug discovery, where large chemical libraries are screened for agonist, antagonist, or allosteric modulator activity. HTS has been instrumental in identifying ligands for GPCRs, ion channels, and nuclear receptors.

6.2 Structure-Based Drug Design (SBDD)

Structure-based drug design leverages detailed 3D structural information of receptors—often obtained through X-ray crystallography, cryo-electron microscopy (cryo-EM), or nuclear magnetic resonance (NMR)—to design ligands that optimally interact with the receptor's binding site. SBDD enables rational drug development by allowing medicinal chemists to tailor molecular interactions, improve binding affinity, and enhance selectivity.

Example: The development of selective kinase inhibitors (e.g., imatinib for BCR-ABL) was greatly facilitated by knowledge of the enzyme’s active site structure.

6.3 Computational Modeling and In Silico Screening

Computational methods such as molecular docking, molecular dynamics simulations, quantitative structure-activity relationship (QSAR) modeling, and virtual screening are integral to modern drug discovery. These in silico tools predict how candidate compounds will interact with receptor binding sites, helping prioritize molecules before synthesis and experimental validation.
Such approaches reduce cost and time, enhance hit-to-lead progression, and are especially valuable for receptors lacking high-resolution structural data.

6.4 Pharmacogenomics

Pharmacogenomics involves the study of genetic variations, particularly single nucleotide polymorphisms (SNPs), that influence individual responses to drugs. Receptor polymorphisms can alter ligand binding, receptor expression, and downstream signaling, thereby affecting therapeutic efficacy and the risk of adverse effects. By integrating pharmacogenomic data into drug development, researchers can identify patient subpopulations that may benefit from or be harmed by specific receptor-targeted therapies—paving the way for personalized medicine.
Example: Variations in β2-adrenergic receptor (ADRB2) genes can influence individual responses to β2-agonists in asthma management. While receptor-targeted pharmacotherapy has transformed modern medicine, it is not without significant limitations. The complexity of receptor biology and inter-individual variability in response to receptor modulators pose major challenges in clinical practice. Several key issues are outlined below:

7. Challenges In Receptor-Targeted Pharmacotherapy

7.1 Receptor Heterogeneity

Receptor expression varies not only between tissue types but also among individuals due to genetic, epigenetic, and pathological factors. This receptor heterogeneity affects drug efficacy and safety:

• A drug may produce the desired effect in one tissue but cause adverse effects in another due to differential receptor subtype distribution.
• For instance, β-adrenergic receptors are expressed differently in cardiac, pulmonary, and vascular tissues, complicating selective targeting.
• Inter-individual variations in receptor density or polymorphisms (e.g., in β2-adrenergic or dopamine D2 receptors) can lead to inconsistent therapeutic outcomes.

7.2 Desensitization and Tachyphylaxis

Prolonged or repeated exposure to receptor agonists often leads to desensitization, a process by which receptors become less responsive to stimulation. This can evolve into tachyphylaxis, where there is a rapid and short-term loss of drug effectiveness. Mechanisms include:

• Receptor phosphorylation by G-protein-coupled receptor kinases (GRKs),
• β-arrestin recruitment and receptor internalization,
• Downregulation of receptor gene expression.

This is particularly problematic in the chronic use of drugs like:

• β2-agonists in asthma,
• Opioids, which lead to tolerance and dependence,
  necessitating dose escalation and increasing the risk of toxicity.

7.3 Off-Target Effects and Cross-Reactivity

Despite improvements in drug design, many receptor-targeted agents still exhibit off-target effects, binding to unintended receptors or molecular pathways. This lack of absolute specificity can result in:

• Unwanted pharmacological actions (e.g., sedation due to histamine H1 receptor binding by antipsychotics),
• Toxicities, particularly in polypharmacy settings,
• Interference with physiological homeostasis.

Cross-reactivity among structurally similar receptors (e.g., serotonin receptor subtypes, muscarinic receptors) remains a major obstacle in achieving precise therapeutic actions.

7.4 Resistance Mechanisms

Resistance to receptor-targeted therapies, especially in oncology and infectious diseases, is a major cause of therapeutic failure. Mechanisms include:

• Receptor mutation (e.g., EGFR T790M mutation in lung cancer conferring resistance to TKIs),
• Receptor downregulation or alteration in expression,
• Activation of compensatory pathways, bypassing the blocked receptor-mediated signal.

In microbial infections, receptor-targeted drugs may become ineffective due to receptor mimicry, efflux pumps, or biofilm formation, which collectively reduce drug-receptor engagement.

These challenges underscore the need for:

• Advanced biomarker identification,
• Combination therapy strategies,
• Continuous monitoring of receptor status,
• Personalized medicine approaches based on receptor profiling and patient genomics.

8. Future Directions

A. Therapeutic Innovation

• Multi-target Ligands
  Development of single drugs that can act on multiple receptors or pathways to treat complex and multifactorial diseases.
• mRNA-Based Receptor Therapy
  Emerging use of synthetic mRNA to modulate or express therapeutic receptors in target cells.

B. Personalized Medicine

• Genomics-Based Receptor Therapy
  Tailoring drug therapies to individual receptor polymorphisms and gene expression profiles for optimal efficacy and reduced toxicity.

C. Technological Advancements

• Biosensors
  Real-time monitoring of receptor-ligand interactions and cellular responses using advanced receptor-based biosensors.
• Nanotechnology
  Targeted drug delivery systems using receptor-specific nanoparticles for enhanced precision and reduced side effects.

10. CONCLUSION

Receptors remain the cornerstone of modern pharmacotherapy, offering precise control over physiological and pathological processes. Advances in molecular pharmacology, structural biology, and computational sciences have enhanced our ability to target receptors with unprecedented specificity. Continued exploration of receptor mechanisms, modulators, and interactions will pave the way for innovative, safer, and more effective therapeutics in the era of precision medicine.

A. Central Role of Receptors: Receptors are pivotal in mediating drug effects and are fundamental targets in pharmacotherapy.

B. Scientific Advancements: Progress in molecular pharmacology, structural biology, and computational drug design has revolutionized receptor targeting.

C. Therapeutic Precision: Modern techniques allow for unprecedented specificity in receptor modulation, minimizing side effects and enhancing therapeutic benefits.

D. Future Perspective: Ongoing research into receptor behavior and modulation is critical to developing innovative, safe, and effective drugs aligned with the goals of precision medicine.

REFERENCES

1. Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang and Dale’s Pharmacology. 9th ed. Elsevier; 2019.
2. Katzung BG. Basic and Clinical Pharmacology. 15th ed. McGraw Hill Education; 2021.
3. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill Education; 2018.
4. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's Manual of Pharmacology and Therapeutics. McGraw-Hill; 2016.
5. Neal MJ. Medical Pharmacology at a Glance. 8th ed. Wiley-Blackwell; 2020.
6. Nierenberg DW, et al. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 5th ed. Wolters Kluwer; 2023.
7. Satoskar RS, Bhandarkar SD, Rege NN. Pharmacology and Pharmacotherapeutics. 26th ed. Elsevier India; 2021.
8. Tripathi KD. Essentials of Medical Pharmacology. 9th ed. Jaypee Brothers Medical Publishers; 2023.
9. Lippincott Illustrated Reviews: Pharmacology. 8th ed. Wolters Kluwer; 2022.
10. Rang HP. Drug Discovery and Development: Technology in Transition. 2nd ed. Elsevier; 2012.
11. Kenakin T. A Pharmacology Primer: Techniques for More Effective and Strategic Drug Discovery. 4th ed. Academic Press; 2014.
12. Luttrell LM. Reviews in endocrine and metabolic disorders. Signal transduction via G protein-coupled receptors. 2005;6(3):233–240.
13. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002;3(9):639–650.
14. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov. 2002;1(3):198–210.
15. Wootten D, Christopoulos A, Sexton PM. Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov. 2013;12(8):630–644.
16. Tschöp MH, et al. GLP-1 receptor agonists for the treatment of obesity and type 2 diabetes. Nat Rev Endocrinol. 2016;12(12):752–765.
17. Schmid CL, et al. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell. 2017;171(5):1165–1175.e13.
18. Tardif JC, et al. Angiotensin receptor blockers in cardiovascular disease: current status and future perspectives. Nat Rev Cardiol. 2014;11(7):414–428.
19. Moustakas DT, et al. Structure-based design of allosteric modulators of GPCRs. Curr Opin Pharmacol. 2015;23:38–45.
20. Mullard A. mRNA vaccines enter the post-pandemic reality. Nat Rev Drug Discov. 2023;22(5):327–330.
21. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117–1134.
22. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25(3):282–303.
23. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61.
24. Wei SC, et al. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086.
25. Marabelle A, et al. PD-1 and PD-L1 blockade for cancer therapy: mechanisms, efficacy, and limitations. Immunity. 2020;52(5):804–817.
26. Hughes JP, et al. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239–1249.
27. Ekins S, et al. Computational drug repurposing: current trends. Drug Discov Today. 2020;25(8):1273–1281.
28. Sliwoski G, et al. Computational methods in drug discovery. Pharmacol Rev. 2014;66(1):334–395.
29. Kobilka BK. The structural basis of G-protein-coupled receptor signaling (Nobel Lecture). Angew Chem Int Ed Engl. 2013;52(25):6380–6388.
30. Jacobson KA, Gao ZG. G protein–coupled adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5(3):247–264.
31. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev. 2001;53(1):1–24.
32. Hollingsworth SA, Dror RO. Molecular dynamics simulation for allosteric drug discovery. Curr Opin Struct Biol. 2018;52:128–133.
33. Li J, et al. Drug resistance in cancer: mechanisms and reversal strategies. Front Pharmacol. 2021;12:690685.
34. Ramakrishnan V, et al. Receptor downregulation and internalization: mechanisms and drug implications. J Pharmacol Exp Ther. 2019;370(1):1–8.
35. Urban JD, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 2007;320(1):1–13.
36. Kenakin T. Biased receptor signaling in drug discovery. Pharmacol Rev. 2019;71(2):267–315.
37. Michel MC, et al. Biased agonism: translating receptor pharmacology into new therapeutics. Pharmacol Rev. 2020;72(2):665–698.
38. Stahl SM. Stahl’s Essential Psychopharmacology. 5th ed. Cambridge University Press; 2021.
39. Insel TR. The revolution in neuroscience: from neurotransmitters to neurocircuits. Science. 2010;327(5961):1079–1080.
40. Drevets WC, et al. Neuroimaging abnormalities in the amygdala in mood disorders. Biol Psychiatry. 2008;63(7):655–660.
41. Holscher C. Insulin signaling in the brain and its role in neurodegeneration. Trends Pharmacol Sci. 2020;41(3):145–158.
42. Martin P, et al. Targeting histamine H1 receptors in allergic inflammation. Allergy. 2011;66(4):469–478.
43. Zheng W, Thorne N, McKew JC. Phenotypic screens as a renewed approach for drug discovery. Drug Discov Today. 2013;18(21–22):1067–1073.
44. Ingber DE. Is it time for reviewer 3 to request organ-on-a-chip data? Nat Rev Drug Discov. 2022;21(3):155–156.
45. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov. 2014;13(10):759–780.
46. Khanna I. Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov Today. 2012;17(19-20):1088–1102.
47. Csermely P, et al. Structure and dynamics of molecular networks: a novel paradigm of drug discovery. Pharmacol Ther. 2013;138(3):333–408.
48. Ecker GF, Chiba P, eds. Transporters as Drug Targets. Wiley-VCH; 2020.
49. Huggins DJ. Structural bioinformatics for drug discovery. Biochim Biophys Acta. 2016;1864(9):1479–1486.
50. Shastri A, et al. Applications of artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26(1):80–93.
51. Smalley JL, et al. Nanomedicine in receptor-targeted therapies: mechanisms and advances. Adv Drug Deliv Rev. 2021;177:113926.
52. Fröhlich H, et al. Computational approaches for receptor binding site prediction and drug repurposing. Front Bioeng Biotechnol. 2020;8:273.